LMAT has a Sell rating from Zacks Rank, poor Value grade (D), significantly higher forward P/E ratio (28.10), and elevated PEG ratio (2.34), suggesting the stock is overvalued relative to its earnings growth and fundamentals.
Strong Q1 results with 11% organic sales growth, 42% EPS growth, 350 bps gross margin expansion, and raised full-year guidance indicating 12% sales growth and 26% adjusted EPS growth. Artegraft product line grew 36% globally. Company also announced dividend increase and $100mm buyback authorization, demonstrating confidence in financial performance and shareholder returns.
Strong financial performance with 16% Q4 sales growth, 47% operating income increase, $250M annual revenue, improved margins, better-than-expected 2026 guidance ($280M projected sales), 25% dividend increase, and $100M buyback program. Insider sale appears routine and unrelated to fundamental concerns. Stock up 30% year-over-year reflects solid execution and market confidence.
The company's active participation in multiple high-profile investor conferences demonstrates management engagement with the investment community and confidence in the business. This level of conference participation typically indicates positive momentum and investor interest in the company's growth prospects.
Articles that tag LMAT but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
